{"id":"NCT02516046","sponsor":"Avid Radiopharmaceuticals","briefTitle":"18F-AV-1451 Autopsy Study","officialTitle":"A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2018-06-13","completion":"2018-07-15","firstPosted":"2015-08-05","resultsPosted":"2020-09-07","lastUpdate":"2020-09-07"},"enrollment":156,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Flortaucipir F18","otherNames":["[F-18]T807","18F-AV-1451","LY3191748"]},{"type":"PROCEDURE","name":"PET Scan","otherNames":[]}],"arms":[{"label":"Flortaucipir PET Scan","type":"EXPERIMENTAL"}],"summary":"This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.","primaryOutcome":{"measure":"Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score)","timeFrame":"at autopsy within 9 months of baseline scan","effectByArm":[{"arm":"Sensitivity of Flortaucipir vs Autopsy NFT Score B3","deltaMin":97.4,"sd":null},{"arm":"Specificity of Flortaucipir vs Autopsy NFT Score <B3","deltaMin":68,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":31,"countries":["United States","Australia"]},"refs":{"pmids":["22265587","22101365","32338734","32542468"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":156},"commonTop":["agitation","headache","myocardial infarction","vertigo","diarrhoea"]}}